McKesson (MCK)
(Delayed Data from NYSE)
$543.30 USD
+3.36 (0.62%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $543.18 -0.12 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Price, Consensus and EPS Surprise
MCK 543.30 +3.36(0.62%)
Will MCK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for MCK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MCK
McKesson (MCK) Rises But Trails Market: What Investors Should Know
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
MCK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why McKesson (MCK) is a Top Momentum Stock for the Long-Term
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
Why McKesson (MCK) is a Top Value Stock for the Long-Term
Other News for MCK
ClearBridge Global Growth Strategy Q1 2024 Portfolio Manager Commentary
June 7th Options Now Available For McKesson Corp (MCK)
Dividend Roundup: MetLife, General Motors, Pfizer, Citigroup, and more
McKinsey Faces Criminal Probe By DOJ For Opioid Consulting: Report
Walgreens expands specialty pharmacy with unit dedicated to cell and gene therapies